3527 related articles for article (PubMed ID: 18539917)
1. Effects of intensive glucose lowering in type 2 diabetes.
; Gerstein HC; Miller ME; Byington RP; Goff DC; Bigger JT; Buse JB; Cushman WC; Genuth S; Ismail-Beigi F; Grimm RH; Probstfield JL; Simons-Morton DG; Friedewald WT
N Engl J Med; 2008 Jun; 358(24):2545-59. PubMed ID: 18539917
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of intensive glucose lowering on cardiovascular outcomes.
; Gerstein HC; Miller ME; Genuth S; Ismail-Beigi F; Buse JB; Goff DC; Probstfield JL; Cushman WC; Ginsberg HN; Bigger JT; Grimm RH; Byington RP; Rosenberg YD; Friedewald WT
N Engl J Med; 2011 Mar; 364(9):818-28. PubMed ID: 21366473
[TBL] [Abstract][Full Text] [Related]
3. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
; Patel A; MacMahon S; Chalmers J; Neal B; Billot L; Woodward M; Marre M; Cooper M; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Liu L; Mancia G; Mogensen CE; Pan C; Poulter N; Rodgers A; Williams B; Bompoint S; de Galan BE; Joshi R; Travert F
N Engl J Med; 2008 Jun; 358(24):2560-72. PubMed ID: 18539916
[TBL] [Abstract][Full Text] [Related]
4. Glucose control and vascular complications in veterans with type 2 diabetes.
Duckworth W; Abraira C; Moritz T; Reda D; Emanuele N; Reaven PD; Zieve FJ; Marks J; Davis SN; Hayward R; Warren SR; Goldman S; McCarren M; Vitek ME; Henderson WG; Huang GD;
N Engl J Med; 2009 Jan; 360(2):129-39. PubMed ID: 19092145
[TBL] [Abstract][Full Text] [Related]
5. Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.
Reaven PD; Emanuele NV; Wiitala WL; Bahn GD; Reda DJ; McCarren M; Duckworth WC; Hayward RA;
N Engl J Med; 2019 Jun; 380(23):2215-2224. PubMed ID: 31167051
[TBL] [Abstract][Full Text] [Related]
6. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.
Hayward RA; Reaven PD; Wiitala WL; Bahn GD; Reda DJ; Ge L; McCarren M; Duckworth WC; Emanuele NV;
N Engl J Med; 2015 Jun; 372(23):2197-206. PubMed ID: 26039600
[TBL] [Abstract][Full Text] [Related]
7. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
[TBL] [Abstract][Full Text] [Related]
9. Effects of intensive blood-pressure control in type 2 diabetes mellitus.
; Cushman WC; Evans GW; Byington RP; Goff DC; Grimm RH; Cutler JA; Simons-Morton DG; Basile JN; Corson MA; Probstfield JL; Katz L; Peterson KA; Friedewald WT; Buse JB; Bigger JT; Gerstein HC; Ismail-Beigi F
N Engl J Med; 2010 Apr; 362(17):1575-85. PubMed ID: 20228401
[TBL] [Abstract][Full Text] [Related]
10. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Pfeffer MA; Claggett B; Diaz R; Dickstein K; Gerstein HC; Køber LV; Lawson FC; Ping L; Wei X; Lewis EF; Maggioni AP; McMurray JJ; Probstfield JL; Riddle MC; Solomon SD; Tardif JC;
N Engl J Med; 2015 Dec; 373(23):2247-57. PubMed ID: 26630143
[TBL] [Abstract][Full Text] [Related]
11. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; McGuire DK;
JAMA; 2019 Jan; 321(1):69-79. PubMed ID: 30418475
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
[TBL] [Abstract][Full Text] [Related]
13. Basal insulin and cardiovascular and other outcomes in dysglycemia.
; Gerstein HC; Bosch J; Dagenais GR; Díaz R; Jung H; Maggioni AP; Pogue J; Probstfield J; Ramachandran A; Riddle MC; Rydén LE; Yusuf S
N Engl J Med; 2012 Jul; 367(4):319-28. PubMed ID: 22686416
[TBL] [Abstract][Full Text] [Related]
14. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.
Miller ME; Bonds DE; Gerstein HC; Seaquist ER; Bergenstal RM; Calles-Escandon J; Childress RD; Craven TE; Cuddihy RM; Dailey G; Feinglos MN; Ismail-Beigi F; Largay JF; O'Connor PJ; Paul T; Savage PJ; Schubart UK; Sood A; Genuth S;
BMJ; 2010 Jan; 340():b5444. PubMed ID: 20061360
[TBL] [Abstract][Full Text] [Related]
15. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB; Bethel MA; Armstrong PW; Buse JB; Engel SS; Garg J; Josse R; Kaufman KD; Koglin J; Korn S; Lachin JM; McGuire DK; Pencina MJ; Standl E; Stein PP; Suryawanshi S; Van de Werf F; Peterson ED; Holman RR;
N Engl J Med; 2015 Jul; 373(3):232-42. PubMed ID: 26052984
[TBL] [Abstract][Full Text] [Related]
16. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Husain M; Birkenfeld AL; Donsmark M; Dungan K; Eliaschewitz FG; Franco DR; Jeppesen OK; Lingvay I; Mosenzon O; Pedersen SD; Tack CJ; Thomsen M; Vilsbøll T; Warren ML; Bain SC;
N Engl J Med; 2019 Aug; 381(9):841-851. PubMed ID: 31185157
[TBL] [Abstract][Full Text] [Related]
17. Severe Hypoglycemia Attributable to Intensive Glucose-Lowering Therapy Among US Adults With Diabetes: Population-Based Modeling Study, 2011-2014.
Mahoney GK; Henk HJ; McCoy RG
Mayo Clin Proc; 2019 Sep; 94(9):1731-1742. PubMed ID: 31422897
[TBL] [Abstract][Full Text] [Related]
18. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.
Bonds DE; Miller ME; Bergenstal RM; Buse JB; Byington RP; Cutler JA; Dudl RJ; Ismail-Beigi F; Kimel AR; Hoogwerf B; Horowitz KR; Savage PJ; Seaquist ER; Simmons DL; Sivitz WI; Speril-Hillen JM; Sweeney ME
BMJ; 2010 Jan; 340():b4909. PubMed ID: 20061358
[TBL] [Abstract][Full Text] [Related]
19. Effect of nateglinide on the incidence of diabetes and cardiovascular events.
; Holman RR; Haffner SM; McMurray JJ; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
N Engl J Med; 2010 Apr; 362(16):1463-76. PubMed ID: 20228402
[TBL] [Abstract][Full Text] [Related]
20. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
Ismail-Beigi F; Craven T; Banerji MA; Basile J; Calles J; Cohen RM; Cuddihy R; Cushman WC; Genuth S; Grimm RH; Hamilton BP; Hoogwerf B; Karl D; Katz L; Krikorian A; O'Connor P; Pop-Busui R; Schubart U; Simmons D; Taylor H; Thomas A; Weiss D; Hramiak I;
Lancet; 2010 Aug; 376(9739):419-30. PubMed ID: 20594588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
